2 recruiting, 1 not yet recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Recruiting 2, Not yet recruiting 1 |
Follow Obrixtamig: new trials by email Literature Review of Obrixtamig trials Research Report on Obrixtamig
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With Obrixtamig Obrixtamig, Ezabenlimab, Atezolizumab - Advanced Cancer | Phase 3 | Not yet recruiting | Boehringer Ingelheim | 68 | 2027-03-04 | 2026-11-10 |
| DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy Obrixtamig, Carboplatin, Etoposide - Extrapulmonary Neuroendocrine Cancer (epNEC) | Phase 3 | Recruiting | Boehringer Ingelheim | 390 | 2026-07-10 | 2026-11-10 |
| DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy obrixtamig, atezolizumab, carboplatin - Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC) | Phase 3 | Recruiting | Boehringer Ingelheim | 670 | 2026-04-13 | 2026-11-10 |
Belgium (3) · France (3) · Germany (3) · Japan (3) · Poland (3) · Spain (3) · Argentina (2) · Australia (2) · Austria (2) · Brazil (2) · Canada (2) · Chile (2) · China (2) · Czechia (2) · Finland (2)
2025 (2)